SynthesisWorld journal of urology2020
The use of mirabegron in neurogenic bladder: a systematic review.
Synthesis in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2025Guideline
- Safety and efficacy of beta-3 adrenergic agonists in treating neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis.Investigative and clinical urology · 2024Pooled it
- Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.International urology and nephrology · 2021Trial
- Urodynamics assessment in patients with multiple sclerosis.BJUI compass · 2026Article
- Eco-friendly spectrophotometric quantification of the potential combination of mirabegron and tamsulosin.Scientific reports · 2025Article
- Urodynamic evaluation of neurogenic bladder in patients with spinal cord injury within 6 months post-injury: a Retrospective Cross-Sectional Study.Spinal cord · 2025Article
- Neurogenic Bladder in Children with Myelomeningocele.Diseases (Basel, Switzerland) · 2025Review
- Green HPLC technique development for the simultaneous determination of the potential combination of Mirabegron and Tamsulosin.Scientific reports · 2025Article
- Targeting neurotrophin and nitric oxide signaling to promote recovery and ameliorate neurogenic bladder dysfunction following spinal cord injury - Mechanistic concepts and clinical implications.Continence (Amsterdam, Netherlands) · 2023Article
- Conservative Bladder Management and Medical Treatment in Chronic Spinal Cord Injury Patients.Journal of clinical medicine · 2023Review
- Current Surgical Treatment for Neurogenic Lower Urinary Tract Dysfunction in Patients with Chronic Spinal Cord Injury.Journal of clinical medicine · 2023Article
- Long-Term Surveillance and Management of Urological Complications in Chronic Spinal Cord-Injured Patients.Journal of clinical medicine · 2022Review
- Bladder Management Strategies for Urological Complications in Patients with Chronic Spinal Cord Injury.Journal of clinical medicine · 2022Review
- Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.IJU case reports · 2021Article
- Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.Journal of medical case reports · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the use of mirabegron in patients with neurogenic bladder.
methodsA systematic review of the literature was conducted using four databases (Medline via PubMed, Scopus, Cochrane, and EMBASE). Articles evaluating mirabegron in neurogenic bladder patients were collected, and assessment of the drug's efficacy was reviewed according to clinical and urodynamic parameters.
resultsSeven studies were selected and a total of 302 patients with NB were evaluated, ranging from 15 to 66 patients per study. All of the patients had received antimuscarinics as a previous treatment modality. Mirabegron was used as a second-line treatment after antimuscarinics lacked efficacy or caused adverse effects. The duration of the treatments ranged from 4 to 12 weeks. Reported in two studies each, bladder compliance and maximal cystometric capacity were the most commonly improved urodynamic parameters. In the majority of the studies, positive outcomes were reported for clinical scores. Additionally, analysis of the IPSS subscores revealed an improvement of storage symptoms as opposed to voiding symptoms. In all of the studies, mirabegron was well tolerated.
conclusionMirabegron appears to be an effective treatment in the management of neurogenic bladder unresponsive to antimuscarinics, particularly in patients presenting with storage symptoms. There is still no evidence concerning the use of mirabegron as a first-line therapy for neurogenic bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.